Literature DB >> 12687010

Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.

Gerald E Stoica1, Thomas F Franke, Anton Wellstein, Elisha Morgan, Frank Czubayko, Heinz-Joachim List, Ronald Reiter, Mary Beth Martin, Adriana Stoica.   

Abstract

This study examines whether the serine/threonine protein kinase, Akt, is involved in the crosstalk between the ErbB2 and estrogen receptor-alpha (ER-alpha) pathways. Treatment of MCF-7 cells with 10(-9) M heregulin-beta1 (HRG-beta1) resulted in a rapid phosphorylation of Akt and a 15-fold increase in Akt activity. Akt phosphorylation was blocked by inhibitors of phosphatidylinositol 3-kinase (PI 3-K), by antiestrogens, the protein tyrosine kinase inhibitor, genistein, and by AG825, a selective ErbB2 inhibitor; but not by AG30, a selective EGFR inhibitor. Akt phosphorylation by HRG-beta1 was abrogated by an arginine to cysteine mutation (R25C) in the pleckstrin homology (PH) domain of Akt, and HRG-beta1 did not induce Akt phosphorylation in the ER-negative variant of MCF-7, MCF-7/ADR. Transient transfection of ER-alpha into these cells restored Akt phosphorylation by HRG-beta1, suggesting the requirement of ER-alpha. HRG-beta1 did not activate Akt in MCF-7 cells stably transfected with an anti-ErbB2-targeted ribozyme, further confirming a role for ErbB2. Stable transfection of the cells with a dominant negative Akt or with the R25C-Akt mutant, as well as PI 3-K inhibitors, blocked the effect of HRG-beta1 on ER-alpha expression and activity and on the growth of MCF-7 cells. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of HRG-beta1. Experiments employing selective ErbB inhibitors demonstrate that the effect of HRG-beta1 on ER-alpha expression and activity is also mediated by ErbB2 and not by EGFR, demonstrating that ErbB2 is the primary mediator of the effects of HRG-beta1 on ER-alpha regulation. Taken together, our data suggest that HRG-beta1, bound to the ErbB2 ErbB3 heterodimer, in the presence of membrane ER-alpha, interacts with and activates PI 3-K/Akt. Akt leads to nuclear ER-alpha phosphorylation, thereby altering its expression and transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687010     DOI: 10.1038/sj.onc.1206311

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.

Authors:  Julia A Beaver; Ben H Park
Journal:  Future Oncol       Date:  2012-06       Impact factor: 3.404

Review 2.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 3.  Multi-targeted therapy of cancer by genistein.

Authors:  Sanjeev Banerjee; Yiwei Li; Zhiwei Wang; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2008-05-19       Impact factor: 8.679

4.  Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt.

Authors:  Romaine Ingrid Fernando; Jay Wimalasena
Journal:  Mol Biol Cell       Date:  2004-04-30       Impact factor: 4.138

5.  Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Authors:  M K Robinson; K M Hodge; E Horak; A L Sundberg; M Russeva; C C Shaller; M von Mehren; I Shchaveleva; H H Simmons; J D Marks; G P Adams
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

6.  Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer.

Authors:  Julia M W Gee; Martin G Giles; Robert I Nicholson
Journal:  Breast Cancer Res       Date:  2004-06-09       Impact factor: 6.466

7.  ERalpha increases expression and interacts with TERT in cataractous canine lens epithelial cells.

Authors:  Carmen M H Colitz; Yasuro Sugimoto; Ping Lu; Curtis Andrew Barden; Jennifer Thomas-Ahner; Heather Lynn Chandler
Journal:  Mol Vis       Date:  2009-11-09       Impact factor: 2.367

8.  Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.

Authors:  Alexey Goltsov; Simon P Langdon; Gregory Goltsov; David J Harrison; James Bown
Journal:  Front Oncol       Date:  2014-02-05       Impact factor: 6.244

9.  Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.

Authors:  Wei Wu; Heran Deng; Nanyan Rao; Na You; Yaping Yang; Minghui Cao; Jieqiong Liu
Journal:  Trials       Date:  2017-10-25       Impact factor: 2.279

10.  Investigation of the Antitumor Effects of Tamoxifen and Its Ferrocene-Linked Derivatives on Pancreatic and Breast Cancer Cell Lines.

Authors:  Márton Kalabay; Zsófia Szász; Orsolya Láng; Eszter Lajkó; Éva Pállinger; Cintia Duró; Tamás Jernei; Antal Csámpai; Angéla Takács; László Kőhidai
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.